PolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee
PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Christina Del Vecchio as General Counsel and member of the Executive Committee. She will join PolyPeptide on 1 September 2021 and will also serve as the company’s Corporate Secretary.
PolyPeptide CEO Raymond De Vré comments: “We are excited to welcome Christina who already has a deep knowledge and understanding of our company having worked closely with us on our recent IPO on SIX Swiss Exchange. With her extensive international legal and public company experience as well as her pragmatic and commercial mindset, Christina brings the ideal blend of capabilities for this newly created role, aimed at supporting our organization as we develop and grow our global business.”
Christina Del Vecchio joins PolyPeptide from Niederer Kraft Frey AG, a leading Swiss law firm based in Zurich, where she has worked since 2013, becoming counsel in 2018. Prior to joining Niederer Kraft Frey AG, she was an associate at Latham & Watkins LLP in their London office. Over the course of her career, Christina has advised numerous Swiss and international companies on a wide range of commercial and financing transactions, securities laws, governance, compliance and other legal matters.
Christina graduated from Columbia Law School in 2008, where she was recognized as a James Kent Scholar, and summa cum laude from the University of Florida in 2000 with a Bachelor of Arts. Christina, who was born in 1978 and raised in the U.S., is a Swiss and Swedish citizen.
Contact
Michael Stäheli, Head of Investor Relations & Corporate Communications
michael.staeheli@polypeptide.com, +41 41 723 20 34
About PolyPeptide Group
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 900 employees, its diversity brings breadth, depth of knowledge and experience to the group. PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing. PolyPeptide’s shares (SIX: PPGN) are listed on the Swiss Stock Exchange. For more information, visit polypeptide.com.
Disclaimer
This release contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.
Additional features:
File: PolyPeptide_General_Counsel_EN
End of ad hoc announcement